Immune system disorders: A few cases of anaphylactoid reactions have been reported.
Nervous system disorders: Dysgeusia.
Cardiac disorders: Rare instances of cardiopulmonary arrest and hypotension have been reported following too rapid intravenous administration.
Vascular disorders: Thrombophlebitis has been reported with IV injection. These reactions can be minimized by deep IM injection and avoidance of indwelling intravenous catheters.
Gastrointestinal disorders: Abdominal pain, nausea, vomiting and diarrhea, esophagitis and esophageal ulcer with oral preparations.
Hepatobiliary disorders: Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy.
Skin and subcutaneous tissue disorders: Maculopapular rash and urticaria have been observed during drug therapy. Generalized mild to moderate morbiliform-like skin rashes are the most frequently reported reactions. Rare instances of erythema multiforme have been associated with clindamycin. Pruritus, vaginitis and rare instances of exfoliative and vesiculobullous dermatitis have been reported. Rare cases of toxic epidermal necrolysis and cases of Stevens-Johnson syndrome have been reported during post-marketing surveillance.
General disorders and administration site conditions: Local irritation, pain, abscess formation have been seen with IM injection.
View ADR Monitoring Form